Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2018

Patel SS, Kuo FC, Gibson CJ, Steensma DP, Soiffer RJ, Alyea EP, et al. High -mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood. 2018;131(25):2816-2825.

Gaudino M, Ivascu N, Cushing M, Lau C, Gambardella I, Di Franco A, et al. Retrograde perfusion through superior vena cava reaches the brain during circulatory arrest. J Thorac Dis. 2018;10(3):1563-1568.

Nguyen GH, Mohler A, Leppert M, Parra C, Zeng Y-, Prok L, et al. Index Case of Cutaneous Follicular Mycosis Fungoides With Central Nervous System Involvement and Review of Literature. Am J Dermatopathol. 2018;40(3):185-190.

Wei X, M Calvo-Vidal N, Chen S, Wu G, Revuelta MV, Sun J, et al. Germline Lysine-Specific Demethylase 1 () Mutations Confer Susceptibility to Multiple Myeloma. Cancer Res. 2018;78(10):2747-2759.

Ng SY, Yoshida N, Christie AL, Ghandi M, Dharia NV, Dempster J, et al. Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nat Commun. 2018;9(1):2024.

Bustoros M, Liechty B, Zagzag D, Liu C, Shepherd T, Gruber D, et al. A Rare Case of Composite Dural Extranodal Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Front Neurol. 2018;9:267.

Patel N, Halpern JA, Kasabwala K, Cricco-Lizza E, Herman M, Margolis D, et al. Multiple Regions of Interest on Multiparametric Magnetic Resonance Imaging are Not Associated with Increased Detection of Clinically Significant Prostate Cancer on Fusion Biopsy. J Urol. 2018;200(3):559-563.

Bellazzo A, Di Minin G, Valentino E, Sicari D, Torre D, Marchionni L, et al. Cell-autonomous and cell non-autonomous downregulation of tumor suppressor DAB2IP by microRNA-149-3p promotes aggressiveness of cancer cells. Cell Death Differ. 2018;25(7):1224-1238.

Gordon JK, Martyanov V, Franks JM, Bernstein EJ, Szymonifka J, Magro C, et al. Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial. Arthritis Rheumatol. 2018;70(2):308-316.

Castellino A, Chiappella A, LaPlant BR, Pederson LD, Gaidano G, Macon WR, et al. Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials. Blood Cancer J. 2018;8(11):108.